Synlogic Reports Third Quarter 2024 Financial Results
November 12, 2024 16:35 ET
|
Synlogic, Inc.
WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported...
Synlogic Reports Second Quarter 2024 Financial Results
August 08, 2024 07:00 ET
|
Synlogic, Inc.
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported...
Synlogic Reports First Quarter 2024 Financial Results
May 14, 2024 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported...
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported...
Synlogic Adopts Limited Duration Stockholders Rights Plan
February 20, 2024 12:15 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced...
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
February 08, 2024 16:15 ET
|
Synlogic, Inc.
Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans...
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
February 02, 2024 12:00 ET
|
Synlogic, Inc.
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study ...
Synlogic Provides Corporate Update and Outlook for 2024
January 04, 2024 07:00 ET
|
Synlogic, Inc.
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1...
Synlogic Announces Contract with the Air Force Research Lab
December 27, 2023 07:00 ET
|
Synlogic, Inc.
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
December 07, 2023 07:00 ET
|
Synlogic, Inc.
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE...